4502 武田薬 2019-11-15 20:00:00
PDT説明会（2019年11月15日コビントン開催）プレゼンテーション資料（4/4） [pdf]
Introducing our Covington Manufacturing Facility
Carlos Soto
Covington Site Head
56
This was our starting place in October 2012
57
Our vision and plans for Covington enable us to serve more
patients as we continue to ramp up our operations
Increases capacity for Investment of Manufacturing Takeda will employ
PLASMA-DERIVED $1 BILLION+ campus covers ~1,500 EMPLOYEES
THERAPIES 1 MILLION+ FT2 in Georgia at full ramp up
2012 2014 2016 2018 2020
Commissioning, FDA license &
Ramp up to full
Construction Qualification & commercial
production
Validation production start
58
This is how our site looks today - November 2019
59
Our current footprint allows for further expansion
Today, we manufacture these therapies from plasma proteins
GAMMAGARD Liquid FLEXBUMIN
61
Our facility is vertically integrated
Fully integrated end-to-end production site
• ~1000 employees today
Plasma testing Fractionation Purification Filling Packaging / ramp up plan in place
• Site includes already
approved BioLife testing
and storage facility
Flexible design for future expansion
Fractionation capacity, million liters
Original design basis ~3
Current “optimized” capacity >4
Expansion potential with added investment 10+
62
Video of Covington Manufacturing Facility
63
Creating impact together
Through a dedicated plasma
business unit, we will reimagine
the plasma industry and uncover
the full potential of plasma-
derived therapies to benefit
patients worldwide
64
Q
A
65
Sue Brown Julie Kim Christopher Adrian Murphy Costa Saroukos Carlos Soto
Head, Global President, PDT BU Morabito Head of Plasma Chief Financial Officer Covington Site Head
BioLife Operations Head R&D, PDT Operating Unit,
Global Manufacturing
& Supply
66